» Chordates CSO comments on the start of the study in PM009
» CLS involved in new French study in prostate cancer
» Saniona made further progress in Q3
» Biovica makes rights issue to become cash flow positive
» NLSDays 2023: Positive vibes across the Nordic life science partnering landscape
Read BioStock's weekly newsletter for v.48 here.
Morning news
WntResearch continues to the second dose group in clinical proof of concept study of Foxy-5. Read more.
Mendus and Australasian Leukemia & Lymphoma Group expands the clinical trial of Vididentel as maintenance treatment of AML. Read more.
Toleranzia reports positive feedback from meeting with the Danish Medicines Agency. Read more.
2cureX receives ethical approval for HIPEC clinical trial. Read more.
Active Biotech has entered into a collaboration agreement for a clinical ocular biodistribution study with laquinimod. Read moreThe company has also announced the outcome of the rights issue. Read more.
UsDsign announces that the company expects revenue for the fourth quarter of 2023 to exceed market expectations. Read more.
Attana published the first part of the science behind immunity profiles. Read more. The company has also prepared an EU growth prospectus in connection with the rights issue. Read more.
ProstaLund has recruited Niclas Nystrom to the position of CFO. Read more.
Today the subscription period begins in Gabathers rights issue. Read more.
Stenocare announces the exercise price for warrants of series TO1. Read more.
Today is the last day for trading in subscription rights in Observe Medical. Read more.
Lipigon invites you to a digital company presentation and Q&A today. Read more.